The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy

Journal of Medical Economics

Volumn 10, Issue 4, 2007, Pages 455-473

  Spackman, D Eldon ^a,b   Yeates, Andrew ^c   Rentz, Anne M ^a,d   Hutton, John ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c EISAI CO LTD   (Japan)

^d UBC   (United States)

Author keywords

Cost effectiveness; Epilepsy; Partial seizures; Quality adjusted life years; Utilities

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; LAMOTRIGINE; PLACEBO; ZONISAMIDE;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; MATHEMATICAL MODEL; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STEVENS JOHNSON SYNDROME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 38149082170     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990701659836     Document Type: Article

References (26)

1. Epilepsy Scotland. Available at: http://www.epilepsyscotland.org.uk [accessed 17 August 2006].
2. Semah F, Picot MC, Adam C et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256-1262.
3. Epilepsy Action. Half of UK patients on epilepsy medication 'still having seizures'. Available at: http://www.epilepsy.org.uk/news/archive/20040115. html [accessed 17 August 2006].
4. Biais L, Sheehy O, St-Hilaire JM et al. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. PharmacoEconomics 2005; 23: 493-503.
5. van Hout BA, Gagnon DD, McNulty P et al. The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation. PharmacoEconomics 2003; 21: 315-326.
6. Ekman M, Forsgren L. Economic evidence in epilepsy: a review. European Journal of Health Economics 2004; 5(Suppl. 1): S36-S42.
7. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002; 43(Suppl. 4): 3-9.
8. Begley CE, Famulari M, Annegers JF et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41: 342-351.
9. Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Research 1996; 23: 139-148.
10. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics 1998; 13: 397-409.
11. Brodie MJ, Duncan R, Vespignani H et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31-41.
12. Eisai Europe Ltd. Data on file. London, UK: Eisai Europe Ltd.
13. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-87.
14. Cereghino JJ, Biton V, Abou-Khalil B et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
15. Shorvon SD, Lowenthal A, Janz D et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179-1186.
16. Matsuo F, Bergen D, Faught E et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43: 2284-2291.
17. Selai C, Trimble M, Price M et al. Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Current Medical Research and Opinion 2005; 21: 733-739.
18. Guberman A, Neto W, Gassmann-Mayer C. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurologica Scandinavica 2002; 106: 183-189.
19. General Register Office for Scotland. 2004 Annual review. Chapter 1 - demographic overview. Available at: http://www.gro-scotland.gov.uk/statistics/ publications-and-data/annual-report-publications/rgs-annual-review-2004/ chapter-1/deaths/index.html [accessed 5 September 2006].
20. Mohanraj R, Norrie J, Stephen LJ et al. Mortality in patients with newly diagnosed epilepsy. AES Presentation. Annual AES Meeting; New Orleans, LA, USA. Epilepsia Suppl. 2004.
21. Nilsson L, Farahmand BY, Persson PG et al. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet 1999; 353: 888-893.
22. Netten A, Curtis L. Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care 2003. The University of Kent, Canterbury, UK, 2003.
23. Messenheimer J, Mullens EL, Giorgi L et al. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998; 18: 281-296.
24. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE, London, UK, 2004.
25. Remak E, Hutton J, Price M et al. A Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost-effectiveness of topiramate. European Journal of Health Economics 2003; 4: 271-278.
26. Wilby J, Kainth A, McDaid C et al. National Institute for Health and Clinical Excellence. Assessment report: a rapid and systematic review of the clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults. Available at: http://guidance.nice.org.uk/page.aspx?o=76399 [accessed 15 August 2007].